Verisk Analytics (VRSK)

Nasdaq Industrials Research & Consulting Services S&P 500
$204.59
-6.88 (-3.25%)
Close of Nov 06, 2026 · end-of-day data
SMA 50SMA 2005Y/10Y use weekly candles (10/40-week averages)

Performance

price return
1W+4.2%
1M+16.6%
3M+12.9%
6M+19.0%
YTD-8.5%
1Y-4.4%
3Y-8.0%
5Y-2.7%

Key statistics

Full financials →
Market cap$26.2B
P/E (TTM)31.0
EPS (TTM, diluted)$6.60
P/S8.26
P/B—
EV / EBITDA18.2
Revenue (TTM)$3.18B
Revenue growth+4.9%
Net margin27.7%
ROE—
Debt / equity—
FCF yield4.2%
Dividend yield0.95%
Payout ratio30%
Beta (1Y)-0.58
Volatility (1Y)36.0%
52-week range$155.94 – $227.16
Avg volume (50D)1.26M

Revenue & net income — last 8 quarters

Statements →
Nov 5, 7:17 AM ET

Verisk Analytics Reports Third Quarter 2026 Financial Results

Mixed earnings 2.02

Verisk Analytics reported third-quarter 2026 revenue of $809 million, representing a 5.3% increase compared to the same period last year. Net income decreased 2.8% to $219 million, while diluted adjusted earnings per share rose 14.0% to $1.96. The company maintained its full-year 2026 financial guidance.

  • Revenue reached $809 million for the quarter ended September 30, 2026, up 5.3% year-over-year.
  • Net income was $219 million, down 2.8% from the prior-year period.
  • Diluted adjusted EPS increased 14.0% to $1.96.
  • The company executed a $100 million accelerated share repurchase program during the quarter.
Read the filing on SEC.gov ↗
Oct 29, 5:07 PM ET

Verisk will follow Delaware Supreme Court order on AccuLynx deal, says deal not assured

Negative legal/regulatory 8.01

On October 23, 2026, Verisk issued a statement after the Delaware Supreme Court affirmed the Delaware Chancery Court judgment relating to its AccuLynx (ExactLogix) acquisition. Verisk said it will proceed in accordance with the order, but the filing states the transaction remains subject to customary closing conditions and FTC review and that there is no guarantee it will be completed.

  • October 23, 2026: Verisk issued a press release responding to the Delaware Supreme Court order on the ExactLogix (AccuLynx) merger.
  • The Delaware Supreme Court order affirmed the judgment of the Delaware Chancery Court.
  • Verisk says the transaction remains subject to customary closing conditions and FTC review, and that there is no guarantee it will be completed.
Read the filing on SEC.gov ↗
Sep 8, 4:24 PM ET

Verisk Analytics: Chief Human Relations Officer Sunita Holzer to retire

Neutral leadership Written later 5.02

Verisk Analytics announced on September 2, 2026 that Chief Human Relations Officer Sunita Holzer will retire. Her retirement date will be set after a successor is identified and announced. The filing does not name a successor or give a financial impact.

  • Sunita Holzer, Chief Human Relations Officer, will retire from the company.
  • Holzer joined Verisk in 2021, according to the filing.
  • Official retirement date to be determined after a successor is announced.
  • The filing reports no financial results or guidance changes.
Read the filing on SEC.gov ↗
Jul 29, 7:16 AM ET

Verisk Q2 2026 revenue rises 4.3% to $806 million; GAAP net income falls 9.8%

Mixed earnings Written later 2.02

Verisk reported second-quarter 2026 results for the period ended June 30, 2026, with revenue up 4.3% to $806 million and diluted adjusted EPS up 5.3% to $1.98. GAAP net income fell 9.8% to $229 million and GAAP diluted EPS fell 3.3% to $1.75, which the company attributed mainly to higher net interest expense, a higher tax rate and litigation legal fees. The company reaffirmed its full-year 2026 outlook, which includes adjusted EPS of $7.45 to $7.75.

  • Revenue was $806 million, up 4.3% (5.8% on an organic constant currency basis); underwriting revenue rose 3.5% and claims revenue rose 6.3%.
  • Net income was $229 million, down 9.8%; diluted GAAP EPS was $1.75, down 3.3%.
  • Diluted adjusted EPS was $1.98, up 5.3%; free cash flow was $298 million, up 57.9%.
  • Full-year 2026 guidance was reaffirmed, including total revenue of $3,190 million to $3,240 million; a $200 million accelerated share repurchase was executed in the quarter.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Recent SEC filings

EDGAR ↗

Famous investors who own VRSK

All investors →
InvestorValue% of portfolioLast quarter
Renaissance Technologies $47.81M0.07% Reduced
Ray Dalio Bridgewater Associates $14.91M0.06% New
George Soros Soros Fund Management $5.97M0.07% Reduced

From each investor's latest 13F filing (Q2 2026); positions are as of the quarter end and filed up to 45 days later.

Trades disclosed by members of Congress

All VRSK congressional trades →
TradedMemberTypeAmount
Aug 18, 2026Gilbert Cisneros CA-31Sell (partial)$1,001 – $15,000
Oct 30, 2025Julie Johnson TX-32 · JointSell$1,001 – $15,000
Oct 30, 2025Julie Johnson TX-32 · JointBuy$1,001 – $15,000
Jun 16, 2026Gilbert Cisneros CA-31Buy$1,001 – $15,000
May 15, 2026Gilbert Cisneros CA-31Buy$1,001 – $15,000
Apr 14, 2026Gilbert Cisneros CA-31Sell$1,001 – $15,000
Feb 10, 2026Gilbert Cisneros CA-31Buy$1,001 – $15,000
Jan 09, 2026Gilbert Cisneros CA-31Sell$1,001 – $15,000

From House periodic transaction reports (STOCK Act); amounts are the form's ranges.

Insider transactions

All insider trades →
DateInsiderTypeSharesPriceValue
Nov 02Shavel Lee
Director, Chief Executive Officer
Sell 10b5-13.54K$194.74$688.41K
Oct 15Mann Elizabeth
Chief Financial Officer
Sell 10b5-1400$184.85$73.94K
Sep 30Patiath Pradip
Director
Award156—$0
Sep 30Hendrick Gregory
Director
Award179—$0
Sep 30Purtill Sabra R.
Director
Award194—$0
Sep 30Perry Christopher John
Director
Award156—$0
Sep 30Liss Samuel G
Director
Award156—$0
Oct 01Shavel Lee
Director, Chief Executive Officer
Sell 10b5-13.54K$170.70$603.42K

Prices are end-of-day and split-adjusted. Financial data from Verisk Analytics's SEC XBRL filings. Not investment advice.